Tenax Therapeutics Inc (TENX) Q4 Loss Widens, But Beats Estimates

Tenax Therapeutics Inc (TENX) posted a Q4 2025 GAAP loss of $0.38 per share, wider than $0.18 per share loss reported last year, but beat estimates. The clinical-stage pharmaceutical company develops novel cardiopulmonary therapies in the United States.

Tenax is advancing its pipeline of levosimendan formulations (TNX-101, TNX-102, and TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction, which have completed phase II clinical trials. The company also develops TNX-201 (imatinib), a tyrosine kinase inhibitor for chronic myeloid leukemia treatment.